News
Intra-Cellular Therapies Inc. CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase. CAPLYTA’s strong ...
Intra-Cellular Therapies Inc. CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase. CAPLYTA’s strong ...
Northern Biologics Reports Phase I Data Update for MSC-1, an Anti-LIF Antibody ... September 30 th, 2019 12:00 PM - 1:00 PM Session Location: Poster Area (Hall 4), Fira Gran Via, Poster 1196P ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback